Oruka Therapeutics
ORKA
14 hedge funds and large institutions have $12.4M invested in Oruka Therapeutics in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.04% less ownership
Funds ownership: 0.29% → 0.25% (-0.04%)
13% less funds holding
Funds holding: 16 → 14 (-2)
24% less capital invested
Capital invested by funds: $16.3M → $12.4M (-$3.94M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$80.4K |
| 2 |
BlackRock
New York
|
+$41.3K |
| 3 |
Renaissance Technologies
New York
|
+$29.6K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$28.5K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$558 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$662K |
| 2 |
ACP
Aveo Capital Partners
Englewood,
Colorado
|
-$474K |
| 3 |
Goldman Sachs
New York
|
-$9.49K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.79K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $3.72M | – | – | – |
|
2
Franklin Resources
San Mateo,
California
| $3.04M | – | – | – |
|
|
VMI
3
VHCP Management II
New York
| $2.75M | – | – | – |
|
|
TCM
4
Tekla Capital Management
Boston,
Massachusetts
| $2.03M | – | – | – |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $304K | – | – | – |
|
|
ACP
6
Aveo Capital Partners
Englewood,
Colorado
| $123K | -$474K | -849 | -79% |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $117K | +$558 | +1 | +0.5% |
|
|
8
Renaissance Technologies
New York
| $78K | +$29.6K | +53 | +60% |
|
|
RA
9
Royce & Associates
New York
| $78K | +$80.4K | +144 | New |
|
|
10
Goldman Sachs
New York
| $43K | -$9.49K | -17 | -18% |
|
|
11
BlackRock
New York
| $41K | +$41.3K | +74 | New |
|
|
12
Northern Trust
Chicago,
Illinois
| $28K | +$28.5K | +51 | New |
|
13
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $27K | – | – | – |
|
14
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
RCM
15
RA Capital Management
Boston,
Massachusetts
| – | -$662K | -1,075 | Closed |
|
|
16
UBS Group
Zurich,
Switzerland
| – | -$2.79K | -5 | Closed |
|
ORKA Hedge Fund Activity: Q1 2017 in Review
14 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2017, worth a combined $12.4M — down 24% from $16.3M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ORKA positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $80.4K. The largest seller was RA Capital Management, exiting entirely with an estimated $662K sold.
- 14 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2017, down from 16 in Q4 2016.
- Funds reported $12.4M of Oruka Therapeutics stock for Q1 2017, down 24% quarter-over-quarter.
- 3 funds opened new Oruka Therapeutics positions in Q1 2017 and 2 closed out, a net change of +1 holder.
- The largest Oruka Therapeutics buyer in Q1 2017 was Royce & Associates, an estimated $80.4K added.
- The largest Oruka Therapeutics seller in Q1 2017 was RA Capital Management, an estimated $662K sold.
Based on aggregated 13F filings for Q1 2017.